Costs of outpatient and inpatient MRSA screening and treatment strategies for patients at elective hospital admission - a decision tree analysis
Background Nosocomial infections are among the most common complications in hospitals. A major part is caused by multidrug-resistant organisms (MDRO). MRSA is still the most prominent and frequent MDRO. The early detection of carriers of multidrug-resistant bacteria is an effective measure to reduce nosocomial infections caused by MDRO. For patients who are planning to go to the hospital, an outpatient screening for MDRO and pre-hospital decolonization is recommended. However, the effectiveness of such pre-admission MDRO management in preparation for a planned hospital stay has not yet been sufficiently scientifically examined from an economic perspective. Methods A decision tree will be used to develop scenarios for MDRO screening and treatment in the context of the outpatient and inpatient sectors using MRSA-positive patients as an example. Subsequently, the expected costs for the respective strategy are presented. Results The decision tree analysis shows that the expected costs of outpatient MRSA management are €8.24 and that of inpatient MRSA management are €672.51. Conclusion The forward displacement of the MRSA screening to the ambulatory sector and any subsequent outpatient decolonization for patients with a planned hospitalization is the most cost-effective strategy and should become a standard benefit. Excluding opportunity costs, the expected costs of inpatient MRSA management are €54.94..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
Antimicrobial resistance and infection control - 7(2018), 1 vom: 29. Nov. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hutzschenreuter, Luise [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Admission screening |
|---|
| Anmerkungen: |
© The Author(s). 2018 |
|---|
| doi: |
10.1186/s13756-018-0442-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR032284985 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR032284985 | ||
| 003 | DE-627 | ||
| 005 | 20230625064703.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13756-018-0442-x |2 doi | |
| 035 | |a (DE-627)SPR032284985 | ||
| 035 | |a (SPR)s13756-018-0442-x-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hutzschenreuter, Luise |e verfasserin |0 (orcid)0000-0003-0388-0579 |4 aut | |
| 245 | 1 | 0 | |a Costs of outpatient and inpatient MRSA screening and treatment strategies for patients at elective hospital admission - a decision tree analysis |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s). 2018 | ||
| 520 | |a Background Nosocomial infections are among the most common complications in hospitals. A major part is caused by multidrug-resistant organisms (MDRO). MRSA is still the most prominent and frequent MDRO. The early detection of carriers of multidrug-resistant bacteria is an effective measure to reduce nosocomial infections caused by MDRO. For patients who are planning to go to the hospital, an outpatient screening for MDRO and pre-hospital decolonization is recommended. However, the effectiveness of such pre-admission MDRO management in preparation for a planned hospital stay has not yet been sufficiently scientifically examined from an economic perspective. Methods A decision tree will be used to develop scenarios for MDRO screening and treatment in the context of the outpatient and inpatient sectors using MRSA-positive patients as an example. Subsequently, the expected costs for the respective strategy are presented. Results The decision tree analysis shows that the expected costs of outpatient MRSA management are €8.24 and that of inpatient MRSA management are €672.51. Conclusion The forward displacement of the MRSA screening to the ambulatory sector and any subsequent outpatient decolonization for patients with a planned hospitalization is the most cost-effective strategy and should become a standard benefit. Excluding opportunity costs, the expected costs of inpatient MRSA management are €54.94. | ||
| 650 | 4 | |a Methicillin-resistant |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Outpatient screening |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Decolonization |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Admission screening |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Costs |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Expected costs |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Decision tree analysis |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Flessa, Steffen |4 aut | |
| 700 | 1 | |a Dittmann, Kathleen |4 aut | |
| 700 | 1 | |a Hübner, Nils-Olaf |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Antimicrobial resistance and infection control |d London : Biomed Central, 2012 |g 7(2018), 1 vom: 29. Nov. |w (DE-627)SPR032269641 |w (DE-600)2666706-X |x 2047-2994 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2018 |g number:1 |g day:29 |g month:11 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s13756-018-0442-x |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2018 |e 1 |b 29 |c 11 | ||